PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma

PIM447, a novel PIM kinase inhibitor, demonstrates significant anti-tumor activity in hepatoblastoma by reducing cell viability, proliferation, motility, and cancer stem cell markers while increasing apoptosis. When combined with cisplatin, PIM447 shows enhanced therapeutic efficacy, suggesting potential as a combination therapy for this pediatric liver cancer.